Bakacak Murat, Ercan Önder, Köstü Bülent, Bostancı Mehmet Sühha, İnanç Fatma, Yaylalı Aslı, Serin Salih, Balakan Ozan, Kıran Gürkan
Sütçü İmam University Faculty of Medicine, Department of Obstetrics and Gynecology, Kahramanmaraş, Turkey.
Sakarya University Faculty of Medicine, Department of Obstetrics and Gynecology, Sakarya, Turkey.
Turk J Obstet Gynecol. 2015 Sep;12(3):125-131. doi: 10.4274/tjod.71601. Epub 2015 Sep 15.
The aim of the study was to analyze the anti-angiogenic role of thalidomide and to assess whether thalidomide had any influence on a rat model of surgically-induced endometriosis.
Endometriosis was induced through surgical induction and homologous transplantation in 16 rats. The rats were randomly separated into two groups as thalidomide (n=8) and control (n=8) groups. Using oral gavage, 100 mg/kg thalidomide 0.5 ml was administered to the first group and saline 0.5 ml to the control group. Histopathologic findings and volume analysis of implants were evaluated after 4 weeks. Vascular endothelial growth factor-A (VEGF-A) and oxidative markers were run from the fluid through peritoneal lavage.
The average implant volume decreased significantly in the thalidomide administrated group after treatment (53.3 and 22.9 mm respectively, p=0.012). Significant differences observed in the histopathologic scores of the thalidomide group (3 and 1 respectively, p=0.012) were not observed in the control group. Significant decreases were observed in the levels of VEGF-A and myeloperoxidase (MPO) from oxidative markers (p=0.004, p=0.037, respectively).
Thalidomide provides volumetric and histopathologic recovery in implants particularly because the VEGF inhibition and anti-angiogenic effect, which suggests that it could be effective in the treatment of endometriosis.
本研究旨在分析沙利度胺的抗血管生成作用,并评估沙利度胺对手术诱导的大鼠子宫内膜异位症模型是否有任何影响。
通过手术诱导和同种移植在16只大鼠中诱导子宫内膜异位症。将大鼠随机分为两组,即沙利度胺组(n = 8)和对照组(n = 8)。采用灌胃法,给第一组大鼠灌胃100 mg/kg沙利度胺0.5 ml,给对照组大鼠灌胃生理盐水0.5 ml。4周后评估植入物的组织病理学结果和体积分析。通过腹腔灌洗从液体中检测血管内皮生长因子-A(VEGF-A)和氧化标志物。
治疗后,沙利度胺给药组的平均植入物体积显著减小(分别为53.3和22.9 mm,p = 0.012)。沙利度胺组的组织病理学评分有显著差异(分别为3和1,p = 0.012),而对照组未观察到显著差异。氧化标志物VEGF-A和髓过氧化物酶(MPO)的水平显著降低(分别为p = 0.004,p = 0.037)。
沙利度胺可使植入物在体积和组织病理学方面恢复,特别是因为其抑制VEGF和抗血管生成作用,这表明它可能对子宫内膜异位症的治疗有效。